Advertisement

Heart Failure pp 199-202 | Cite as

Myocardial Revascularization in Patients with Left Ventricular Dysfunction

  • D. ReinekeEmail author
  • T. Carrel
Chapter
Part of the Cardiovascular Medicine book series (CVM)

Abstract

Do patients with ischemic cardiomyopathy benefit from surgical revascularization? This question has been studied extensively over the last 20–30 years and needs to be analyzed from different viewpoints. What is the evidence concerning surgical revascularization of patients with an ejection fraction of 35%? What is the role of percutaneous coronary interventions (PCI) and optimal medical therapy (OMT). What do the guidelines tell us? And are current strategies still timely in view of new developments in the field of end-stage heart failure?

References

  1. 1.
    Velazquez E, Lee L, Jones R, Al-Khalidi H, Hill J, Panza J, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374(16):1511–20.CrossRefGoogle Scholar
  2. 2.
    Aldermann EL, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation. 1983;68:785–95.CrossRefGoogle Scholar
  3. 3.
    The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. Eleven-year survival in the veterans administration randomized trial of coronary bypass surgery for stable angina. N Engl J Med. 1984;311:1333–9.CrossRefGoogle Scholar
  4. 4.
    Varnauskas E, the European Coronary Surgery Study Group. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med. 1988;319:332–7.CrossRefGoogle Scholar
  5. 5.
    Velazquez E, Lee K, Deja M, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607–16.CrossRefGoogle Scholar
  6. 6.
    Elamm C, Fang J. The world post-STITCH: is this a “game changer?” A non-invasive cardiologist’s perspective – revascularisation is the treatment of choice only in patients who fail medical therapy. Prog Cardiovasc Dis. 2013;55:466–9.CrossRefGoogle Scholar
  7. 7.
    Hochman J, Lamas G, Buller C, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395–407.CrossRefGoogle Scholar
  8. 8.
    Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.CrossRefGoogle Scholar
  9. 9.
    Hochmann J, Reynolds H, Dzavik V, et al. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. Circulation. 2011;124(21):2320–8.CrossRefGoogle Scholar
  10. 10.
    Sedlis S, Hartigan P, Teo K, et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med. 2015;373(20):1937–46.CrossRefGoogle Scholar
  11. 11.
    Cleland JG, Calvert M, Freemantle N, et al. The heart failure revascularization trial (HEART). Eur J Heart Fail. 2011;13:227–33.CrossRefGoogle Scholar
  12. 12.
    Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomized controlled trial. Lancet. 2003;362:14–21.CrossRefGoogle Scholar
  13. 13.
    Kunadian V, Pugh A, Zaman AG, Qiu W. Percutaneous coronary intervention among patients with left ventricular systolic dysfunction: a review and meta-analysis of 19 clinical studies. Coron Artery Dis. 2012;23:469–79.CrossRefGoogle Scholar
  14. 14.
    Marui A, Kimura T, Nishiwaki N, et al. Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions≤50% versus >50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol. 2014;114:988–96.CrossRefGoogle Scholar
  15. 15.
    Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH. Drug-eluting stents vs. coronary artery bypass grafting in multivessel coronary disease. N Engl J Med. 2008;358:331–41.CrossRefGoogle Scholar
  16. 16.
    Hlatky MA, Boothroyd DB, Baker L, Kazi DS, Solomon MD, Chang TI, Shilane D, Go AS. Comparative effectiveness of multivessel coronary bypass surgery and multivessel percutaneous coronary intervention a cohort study. Ann Intern Med. 2013;158:727–35.CrossRefGoogle Scholar
  17. 17.
    Nagendran J, Norris CM, Graham MM, Ross DB, Macarthur RG, Kieser TM, Maitland AM, Southern D, Meyer SR. Coronary revascularization for patients with severe left ventricular dysfunction. Ann Thorac Surg. 2013;96:2038–44.CrossRefGoogle Scholar
  18. 18.
    Hlatky M, Boothroyd D, Bravata D, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373:1190–7.CrossRefGoogle Scholar
  19. 19.
    Yang JH, Choi SH, Song YB, Hahn JY, Choi JH, Jeong DS, Sung K, Kim WS, Lee YT, Gwon HC. Long-term outcomes of drug-eluting stent implantation versus coronary artery bypass grafting for patients with coronary artery disease and chronic left ventricular systolic dysfunction. Am J Cardiol. 2013;112:623–9.CrossRefGoogle Scholar
  20. 20.
    Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;124(23):e652–735.PubMedGoogle Scholar
  21. 21.
    Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2014;35:2541–619.CrossRefGoogle Scholar
  22. 22.
    Yancy CW, Jessup M, Bozkurt B, et al. 2013ACCF/AHAguideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327.PubMedGoogle Scholar
  23. 23.
    Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRefGoogle Scholar
  24. 24.
    Estep J, Starling R, Horstmanshof D. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. J Am Coll Cardiol. 2015;66:1747–61.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Cardiovascular SurgeryUniversity Hospital BernBernSwitzerland

Personalised recommendations